BeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c

Reports Q3 revenue $1.4B, consensus $1.36B. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said CEO John Oyler. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL. With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that will drive long-term value.”